Cboe at Barclays conference: focus shifts to derivatives and data

Cboe outlined an organic-growth strategy centered on derivatives, data and new securities-based event products, following the exit of marginal cash-equities businesses. SPX options volume reached a Q2 record of roughly 5 million contracts, with 0DTE accounting for 3.1 million contracts (62%); adjusted operating EBITDA margin was about 72%, up 600bps year over year. DataVantage is outperforming its medium-term trajectory, with about half of new data sales originating overseas, while KPI contracts tied to company metrics await SEC and clearing-agency approvals. Cboe raised its quarterly dividend 19% in August and continues opportunistic buybacks, though regulatory timing and adoption of KPI contracts remain key risks.

Analysis

CBOE's earnings sensitivity is shifting toward recurring, high-incremental-margin data/connectivity revenue and proprietary derivatives rather than transaction volume alone. That mix can support a premium multiple if overseas subscriptions persist, but the near-term acceleration may contain non-recurring historical-data purchases; investors should not capitalize the recent growth rate without separating subscription ARR from catch-up revenue. The strategic simplification also raises operating leverage, although management's willingness to reinvest means consensus margin extrapolation is the more likely source of disappointment than core revenue.

KPI contracts are strategically valuable less for initial fee revenue than for creating a new hedging layer around earnings catalysts and deepening broker/API integration. The critical gating item is dual regulatory approval and clearing authorization; a delay pushes commercialization beyond the market's likely valuation horizon, while approval could make CBOE the regulated beneficiary of demand now flowing to prediction-market and offshore perpetual venues. IBKR and SCHW gain modestly from broader customer engagement, but their economics depend on retail adoption and routing/payment arrangements that remain unproven.

The cleaner relative-value implication is CBOE versus CME. CME has greater macro-rate and commodities exposure, while CBOE has more direct exposure to retail options, index-option liquidity network effects and data monetization; CBOE should outperform in a benign-volatility, retail-risk-taking regime. Contrarily, 0DTE's durability is not equivalent to immunity: a sharp volatility shock, retail loss event, or SEC scrutiny of short-dated/options-linked products could reduce retail participation and compress both volumes and the growth multiple simultaneously.

Over 6-18 months, option-income ETF growth is a structural volume tailwind for listed-options infrastructure, with BLK among the asset-gathering beneficiaries. The offset is cannibalization risk: more systematic overwrite assets can damp realized equity volatility and reduce discretionary hedging demand, making aggregate contract-volume growth less linear than ETF AUM growth. Watch CBOE's data growth composition, SPX market share, and regulatory milestones rather than headline contract volume.

Key Decisions for Investors

• Initiate a 3-6 month long CBOE / short CME pair, sized market-neutral: CBOE has identifiable data and product catalysts while CME lacks comparable retail/index-options optionality. Target 10-15% relative outperformance; exit if DataVantage recurring growth decelerates materially or regulatory review signals substantive objections.
• Add CBOE only on regulatory-date volatility or a post-earnings pullback, not on conference commentary. The upside case requires approval plus evidence of paid KPI-contract liquidity; if approval slips beyond the stated review window or incremental technology/clearing spend drives EBITDA margin down more than 300 bps without revenue traction, cut exposure.
• Maintain a tactical overweight in IBKR versus SCHW over 1-3 months as the more internationally scalable distribution channel for new listed derivatives. This is an adoption watch rather than a KPI-contract revenue call; reassess after broker disclosures show active-user engagement and options commissions/contract volumes.
• Long BLK as a 6-18 month secondary beneficiary of options-based ETF asset growth, but do not use it as a direct CBOE proxy. Falsifier: sustained net outflows or fee compression in defined-outcome and covered-call ETF categories despite industry AUM growth.